WALTHAM, Mass., July 1 /PRNewswire/ -- X-Chem, Inc. today announced the signing of a multi-year collaborative agreement withRoche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets. As part of the agreement, Roche will provide X-Chem with upfront and research payments, success-based discovery
"Entering into our first major alliance with a partner such as Roche is extraordinarily exciting for our company," said Richard W. Wagner, Ph.D., President and CEO of X-Chem. "Roche has an exceptional track record in recognizing and embracing powerful biotechnology innovations. The program that we are developing will establish drug discovery capabilities unique in the industry."
About X-Chem. X-Chem, Inc. is a biotechnology company formed in January 2010 by Richard Wagner, Brant Binder, and Gordon Binder, based in Cambridge, MA. The company's mission is to apply its innovative drug discovery capabilities to the discovery of compounds against novel, proprietary therapeutic targets. X-Chem's initial interest is to screen novel targets in stem cell biology using the recently introduced BIND® Scanner instrument developed and marketed by SRU Biosystems, a label-free, microplate-based system for profiling compounds that affect stem cell growth, health, and differentiation.
SOURCE X-Chem, Inc.
Subscribe to our Free Newsletters!
Craniosynostosis is a condition where the bones of the skull are fused together prematurely ...
Episiotomy is a surgical incision made in the perineum between the vaginal orifice and the anus ...
Stickler syndrome is a rare genetic disorder which causes multisystem disorders predominantly ...View All